key: cord-0937735-fnoatkfh authors: Sahu, Kamal Kant; Borogovac, Azra; Cerny, Jan title: COVID‐19 related immune hemolysis and thrombocytopenia date: 2020-08-16 journal: J Med Virol DOI: 10.1002/jmv.26402 sha: 71731b208e657a03681087f78beb074598cebc99 doc_id: 937735 cord_uid: fnoatkfh The current pandemic due to coronavirus disease 2019 (COVID‐19) has posed an unprecedented challenge for the medical communities, various countries worldwide, and their citizens. Severe acute respiratory syndrome coronavirus 2 has been studied for its various pathophysiological pathways and mechanisms through which it causes COVID‐19. In this study, we discussed the immunological impact of COVID‐19 on the hematological system, platelets, and red blood cells. In our literature search, we found 20 patients with COVID-19 who were reported to have immune dysregulation with the development of ITP, AIHA, and/or Evan's syndrome. In total, there were 10 (50%) patients with ITP, 9 (45%) patients with AIHA, and 1 (5%) patient had Evan's syndrome. The average age of the patients was 61 (17-89 years) years with the majority (55%) being males (11 out of 20). Four out of 20 (20%) patients also had a previous history of autoimmune disease (one each with polymyalgia rheumatica and autoimmune hypothyroidism, and two with chronic ITP). To note, one (5%) patient also had congenital thrombocytopenia. 11 Regarding the underlying malignancies, eight (40%) patients were found to have history of cancers, six with lymphoproliferative disorders (CLL-2, MZL-2, MGUS-1, and ALPS-1) and the remaining two with solid malignancies. The largest case series of AIHA with COVID-19 (7 cases) to date has been reported by Lazarian et al. Our review showed that most patients who had bleeding symptoms only reported of superficial bruising, petechial spots, or hemorrhages. Only 2 patients out of 20 (10%) suffered from intracranial bleeding, one out of which died. Reported nadir platelet counts in ITP cases were extremely variable with as high as 338 000 cells/μL to as low as 0 cell/ μL. Similarly, the lowest reported hemoglobin (2.5 gm/dL) in AIHA with COVID-19 was reported by Wahlster et al. 12 All patients were laboratory-confirmed COVID-19 positive with a positive nasopharyngeal swab. With regard to the management, drugs attempted were steroids (dexamethasone, methylprednisone, and prednisone), intravenous immunoglobulin (IVIG), eltrombopag, and rituximab ( Table 1) . Most of the patients (four out of seven) with AIHA reported by Lazarian et al 10 were receiving treatment at the time of publication. Two patients had a partial response and one patient failed to respond to steroids. All nine patients (100%) with AIHA and 9 of 10 patients (90%) with ITP recovered from the acute crisis and were discharged. Thrombocytopenia is one of the challenging disease entities faced by clinicians in day-to-day clinical practice. 14, 15 Immune-mediated hematologic conditions, characterized by ITP, AIHA, or Evan's syndrome, are known to be associated with previous exposure to various viral infections. Platelet-virus interplay could represent a combination of multiple pathways that may include complement activation, antigen mimicry of platelet surface glycoproteins, consumptive coagulopathy, and direct bone marrow suppression. 16 Similarly, AIHA is a common association with indolent lymphoproliferative disorders, and the coinfection of SARS-CoV-2 could potentially trigger hemolysis (Figure 1 ). Treatment of autoimmune disorders is always challenging in the presence of active infection. Hematologists and other physicians often prefer IVIG as an initial therapy when the concerns of worsening of active infection or risk of acquiring a superadded infection are high. 17, 18 Due to concerns that steroids may worsen the SARS-CoV-2 infection and could lead to acute respiratory distress syndrome, World Health Organization (WHO) recommends against using steroids in COVID-19. 16 In the present patient cohort, most of the patients received steroids for their autoimmune disease and not COVID-19. In conclusion, hematological findings such as thrombocytopenia and anemia in COVID-19 could be due to multiple reasons and timely diagnosis of the immunological cause is essential, so that appropriate immunosuppression can be initiated in a timely fashion. Current perspective on pandemic of COVID-19 in the United States Thrombocytopenia as an initial manifestation of COVID-19; case series and literature review COVID-19-associated immune thrombocytopenia Sudden severe thrombocytopenia in a patient in the recovery stage of COVID-19 Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy-a case report COVID-19 as a cause of immune thrombocytopenia COVID-19 presenting with immune thrombocytopenia: a case report and review of the 1 Mechanisms of SARS-CoV-2 induced thrombocytopenia. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 literature Immune thrombocytopenia due to COVID-19 during pregnancy Immune thrombocytopenic purpura in a patient with Covid-19 Autoimmune haemolytic anaemia associated with COVID-19 infection Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation Evans syndrome in a patient with COVID-19 Rifampin induced thrombotic thrombocytopenic purpura Dasatinib and Dysfunction of Platelets Mechanisms involved in the development of thrombocytopenia in patients with COVID-19 Immune thrombocytopenia as a presenting manifestation of tuberculosis-challenge in resource constraint settings Challenges for management of immune thrombocytopenia during COVID-19 pandemic The authors declare that there are no conflict of interests. http://orcid.org/0000-0002-0382-6882Jan Cerny http://orcid.org/0000-0002-6602-5505